Establishing Endpoints - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Establishing Endpoints


Pharmaceutical Technology Europe
Volume 23, Issue 3

Room for further innovation

Given the way that manufacturing is changing within the industry, real-time, on- and/or in-line instrumentation is becoming increasingly preferred, where its application is feasible. With respect to granulation, on-line NIR detection for moisture content measurement and on- or in-line particle size analysis are both commercially available and applied. As BFE has proven to be a particularly relevant and sensitive tool for monitoring granulation applications, its evolution as an on-line as opposed to at-line method would be a welcome innovation.

As manufacturers increasingly choose to use BFE as part of the specification for granule properties, it is inevitable that more published data correlating BFE with tabletting performance will emerge.

The benefits of accurate endpoint determination

As discussed earlier, if we define endpoint by saying "add x litres of granulation solution and process at an impeller speed of y rpm for z minutes", then each new scale presents a new optimisation challenge because the values of x, y and z will depend on the scale of the granulation process. If, on the other hand, we can define endpoint in terms of a granule property independent of scale, then moving from development to full production is easier. Considering the measurement of granule flow properties, at each stage we are targeting the same BFE as granules made at a small scale that made ideal tablets, rather than using conditions that work only at that smaller scale. This iterative process to reach acceptable processing conditions is therefore accelerated at each scale.

Efficient endpoint detection is, of course, essential for consistent product quality. More than that though, it maximises equipment utilisation, where granulating for just long enough to meet a specification ensures that a unit is not tied up unproductively.

Tim Freeman is Director of Operations at Freeman Technology.

This article is part of a special feature on granulation that was published in the March issue of PTE Digital, available at http://www.pharmtech.com/ptedigital0311


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology Europe,
Click here